The U.S. Food and Drug Administration (FDA) has granted Novartis’ Entresto expanded indication for chronic heart failure, making it the only drug therapy approved in the US to treat patients afflicted with guideline-defined heart failure. Approximately 83% of Americans diagnosed with chronic heart failure can receive Entresto as a treatment option, including those suffering from heart failure with reduced ejection fraction (HFrEF) as well as heart failure with preserved ejection fraction (HFpEF)(1-3). Scott Solomon, MD, Professor of Medicine at Harvard Medical School and Brigham and Women’s Hospital, and PARAGON-HF Executive Committee Co-Chair, stated, “This approval is a significant advancement, providing a treatment to many patients who were not eligible for treatment before because their ejection fraction was above the region we normally considered reduced. Until now, treatment for these patients was largely empiric.”
Read more here.